Dihydroartemisinin-piperaquine or sulphadoxine-pyrimethamine for the chemoprevention of malaria in children with sickle cell anaemia in eastern and southern Africa (CHEMCHA): a protocol for a multi-centre, two-arm, double-blind, randomised, placebo-controlled superiority trial.

Autor: Nkosi-Gondwe T; Training and Research Unit of Excellence, Blantyre, Malawi., Robberstad B; University of Bergen, Bergen, Norway., Opoka R; Makerere University College of Health Sciences, Kampala, Uganda., Kalibbala D; Global Health Uganda, Kampala, Uganda., Rujumba J; Makerere University College of Health Sciences, Kampala, Uganda., Galileya LT; Training and Research Unit of Excellence, Blantyre, Malawi., Akun P; Makerere University College of Health Sciences, Kampala, Uganda., Nambatya W; Makerere University College of Health Sciences, Kampala, Uganda., Ssenkusu J; Makerere University College of Health Sciences, Kampala, Uganda., TerKuile F; Liverpool School of Tropical Medicine, Liverpool, UK., Phiri K; Training and Research Unit of Excellence, Blantyre, Malawi., Idro R; Makerere University College of Health Sciences, Kampala, Uganda. ridro1@gmail.com.
Jazyk: angličtina
Zdroj: Trials [Trials] 2023 Apr 05; Vol. 24 (1), pp. 257. Date of Electronic Publication: 2023 Apr 05.
DOI: 10.1186/s13063-023-07274-4
Abstrakt: Background: An estimated 300,000 babies are born with sickle cell anaemia (SCA) annually. Affected children have chronic ill health and suffer premature death. Febrile illnesses such as malaria commonly precipitate acute crises in children with SCA. Thus, chemoprophylaxis for malaria is an important preventive strategy, but current regimes are either sub-optimally effective (e.g. monthly sulphadoxine-pyrimethamine, SP) or difficult to adhere to (e.g. daily proguanil). We propose dihydroartemisinin-piperaquine (DP) as the agent with the most potential to be used across Africa.
Methods: This will be a randomised, double-blind, parallel-group superiority trial of weekly single-day courses of DP compared to monthly single-day courses of SP in children with SCA. The study will be conducted in eastern (Uganda) and southern (Malawi) Africa using randomisation stratified by body weight and study centre. Participants will be randomised using an allocation of 1:1 to DP or SP. We will investigate the efficacy, safety, acceptability and uptake and cost-effectiveness of malaria chemoprevention with weekly courses of DP vs monthly SP in 548 to 824 children with SCA followed up for 12-18 months. We will also assess toxicity from cumulative DP dosing and the development of resistance. Participant recruitment commenced on 30 April 2021; follow-up is ongoing.
Discussion: At the end of this study, findings will be used to inform regional health policy. This manuscript is prepared from protocol version 2.1 dated 1 January 2022.
Trial Registration: The trial was registered at ClinicalTrials.gov, NCT04844099 . Registered on 08 April 2021.
(© 2023. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje